AD 2022
Alternative Names: AD-2022Latest Information Update: 12 Jul 2024
At a glance
- Originator Addpharma
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential hypertension; Hypercholesterolaemia
Most Recent Events
- 07 Jun 2024 Addpharma completes a phase III trial in Essential hypertension in South Korea (PO) (NCT06448962)
- 07 Jun 2024 Addpharma completes a phase III trial in Hypercholesterolaemia in South Korea (PO) (NCT06448962)
- 22 Oct 2020 Phase-III clinical trials in Essential hypertension in South Korea (PO) (NCT06448962)